Study guide

6.4 Vasoactive Medication Titration (Norepinephrine, Epinephrine, Dopamine)

Certified Flight Paramedic FP-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Safety and Transport

1.1 Pre-Flight Operations and Equipment Stowing 1.2 Scene Safety and Landing Zone Management 1.3 In-Flight Emergency Response and Abort Protocols 1.4 Post-Incident Survival and Rescue Operations

2 Chapter 2: Flight Physiology

2.1 Gas Laws in Transport Medicine 2.2 Hypoxia: Classification and Corrective Actions 2.3 Environmental Stressors of Flight and Cabin Pressurization

3 Chapter 3: Airway, Anesthesia, and Analgesics

3.1 Advanced Airway Assessment and Difficult Airway Algorithms 3.2 Rapid Sequence Intubation (RSI) and Medication Selection 3.3 Mechanical Ventilation: Modes, Settings, and Monitoring 3.4 Transport Oxygen Systems and Duration Calculations 3.5 Anaesthetics and Induction Agents 3.6 Neuromuscular Blocking Agents 3.7 Analgesics and Vasoactive Sedative Titration

4 Chapter 4: Medical Emergencies

4.1 Respiratory Failure Pathologies (ARDS, Asthma, COPD) 4.2 Sepsis and Septic Shock Management 4.3 Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) 4.4 Toxicological Emergencies and Overdose Antidotes 4.5 Environmental Emergencies: Core Temperature Control (Hypo/Hyperthermia) 4.6 Adrenal Crisis and Incretin/Endocrine Emergencies

5 Chapter 5: Neurological Emergencies

5.1 Neurological Assessment and GCS Motor Scales 5.2 Traumatic Brain Injury (TBI) and Intracranial Pressure (ICP) Management 5.3 Stroke Care: Hemorrhagic vs. Ischemic Thrombectomy Candidates 5.4 Status Epilepticus Seizure Protocols 5.5 Spinal Trauma and Spinal Cord Syndromes

6 Chapter 6: Cardiac Emergencies

6.1 Acute Coronary Syndrome (ACS) and 12-Lead Interpretation 6.2 Dysrhythmias: Bradycardias and High-Grade AV Blocks 6.3 Cardiogenic Shock and Systemic Vascular Resistance (SVR) 6.4 Vasoactive Medication Titration (Norepinephrine, Epinephrine, Dopamine) 6.5 Mechanical Circulatory Support (IABP and ECMO Transport) 6.6 Post-Cardiac Arrest Care and Targeted Temperature Management

7 Chapter 7: Trauma/Burn Resuscitation

7.1 Damage Control Resuscitation and the Lethal Triad 7.2 Hemorrhage Control and Massive Transfusion Protocols (MTP) 7.3 Penetrating Thoracic Trauma and Cardiac Tamponade (Beck's Triad) 7.4 Blunt Force Deceleration Injuries (Traumatic Aortic Rupture) 7.5 Burn Physiology: Calculations (Parkland Formula) and Escharotomy

8 Chapter 8: Maternal, Fetal, and Neonatal Emergencies

8.1 Perinatal Transport and Maternal Complications 8.2 Ob/Gyn Emergencies and Emergency Delivery 8.3 Neonatal Resuscitation Program (NRP) Standards

9 Chapter 9: Pediatric Emergencies

9.1 Pediatric Assessment Triangle and Pathophysiology 9.2 Pediatric Airway and Ventilatory Management 9.3 Pediatric Pharmacology and Dosing Calculations 9.4 Pediatric Trauma and Resuscitation

10 Chapter 10: Professional Considerations

10.1 CAMTS Standards and Quality Metrics 10.2 Medical Ethics and Transport Law (EMTALA) 10.3 Crew Resource Management (CRM) and Human Factors

6.4 Vasoactive Medication Titration (Norepinephrine, Epinephrine, Dopamine)

Key Takeaways Explain This Topic AI

Alpha-1 receptor activation causes arterial and venous vasoconstriction, raising SVR, whereas Beta-1 stimulation enhances myocardial contractility and heart rate (increasing MVO2).

Norepinephrine is the first-line vasopressor for septic shock, operating with strong alpha-1 and moderate beta-1 affinity, which minimizes the risk of tachyarrhythmias compared to dopamine.

Epinephrine possesses biphasic properties: at lower doses (< 0.05 mcg/kg/min) beta-1 and beta-2 effects predominate, whereas higher doses stimulate dominant alpha-1 vasoconstriction.

Dopamine acts dose-dependently: 1-5 mcg/kg/min stimulates dopaminergic receptors; 5-10 mcg/kg/min stimulates beta-1 receptors; 10-20 mcg/kg/min stimulates alpha-1 receptors.

Vasoactive extravasation triggers severe local ischemia; management requires stopping the infusion, aspirating remaining drug, and infiltrating the site with phentolamine (Regitine), a competitive alpha-adrenergic blocker.

Last updated: July 2026

6.4 Vasoactive Medication Titration

Vasoactive medications are the cornerstone of hemodynamic management in the critical care transport environment. Flight paramedics must possess a deep, pharmacology-based understanding of receptor dynamics, dosing ranges, and safety protocols to manage shock states. The selection and titration of these agents are driven by their affinity for specific adrenergic and dopaminergic receptors, which directly influence systemic vascular resistance (SVR), heart rate, and myocardial contractility.

Adrenergic and Dopaminergic Receptor Physiology

To effectively manage vasoactive infusions, transport clinicians must understand the distribution and cellular responses of the primary target receptors:

Alpha-1 ( α 1 \alpha_1 α 1 ​ ) Receptors: Located on vascular smooth muscle. Activation triggers a G q G_q G q ​ -coupled protein cascade, leading to phospholipase C activation, release of intracellular calcium, and smooth muscle contraction. This results in profound arterial and venous vasoconstriction, increasing SVR, venous return (preload), and mean arterial pressure (MAP).

Beta-1 ( β 1 \beta_1 β 1 ​ ) Receptors: Primarily localized in the myocardium and cardiac conduction system. Activation initiates a G s G_s G s ​ -coupled protein pathway, elevating cyclic adenosine monophosphate (cAMP) and activating protein kinase A. This increases calcium influx during action potentials, resulting in positive inotropy (contractility), positive chronotropy (heart rate), and positive dromotropy (conduction velocity), thereby increasing myocardial oxygen demand ( M V O 2 MVO_2 M V O 2 ​ ).

Beta-2 ( β 2 \beta_2 β 2 ​ ) Receptors: Found in bronchial and vascular smooth muscle (especially in skeletal muscle beds). Activation leads to cAMP-mediated smooth muscle relaxation, causing bronchodilation and peripheral vasodilation, which can lower SVR.

Dopaminergic ( D 1 D_1 D 1 ​ and D 2 D_2 D 2 ​ ) Receptors: D 1 D_1 D 1 ​ receptors are located in the renal, mesenteric, coronary, and cerebral vascular beds, where their stimulation causes vasodilation. D 2 D_2 D 2 ​ receptors act presynaptically to inhibit norepinephrine release.

Medication α 1 \alpha_1 α 1 ​ Affinity β 1 \beta_1 β 1 ​ Affinity β 2 \beta_2 β 2 ​ Affinity Dopaminergic Affinity

  • Norepinephrine Strong ( + + + + ++++ + + + + ) Moderate ( + + ++ + + ) Negligible ( 0 0 0 ) None
  • Epinephrine Strong ( + + + + ++++ + + + + ) Potent ( + + + + ++++ + + + + ) Moderate ( + + + +++ + + + ) None

Dopamine Dose-dependent ( 0 0 0 to + + + +++ + + + ) Dose-dependent ( 0 0 0 to + + + +++ + + + ) Negligible ( 0 0 0 ) Strong ( + + + + ++++ + + + + )

Norepinephrine (Levophed)

Norepinephrine is the first-line vasopressor for septic, neurogenic, and cardiogenic shock with low SVR. It functions primarily as a potent α 1 \alpha_1 α 1 ​ agonist, causing vasoconstriction that elevates MAP. It also has moderate β 1 \beta_1 β 1 ​ agonist activity, providing mild inotropic support, but the increase in afterload often causes a reflex bradycardia that balances the chronotropic effect.

Dosing: Standard titration ranges from 0.01 to 3.0 mcg/kg/min. In non-weight-based protocols, it is initiated at 2 to 5 mcg/min and titrated up to 30 mcg/min.

Clinical Implications: Norepinephrine increases both venous and arterial tone. Venoconstriction shifts blood from the splanchnic circulation to the central compartment, increasing preload, while arterioloconstriction increases SVR. This dual mechanism effectively restores organ perfusion pressure in vasodilatory states without excessively increasing heart rate, reducing the risk of tachyarrhythmias compared to other agents.

Epinephrine (Adrenaline)

Epinephrine is a non-selective, potent agonist of α 1 \alpha_1 α 1 ​ , β 1 \beta_1 β 1 ​ , and β 2 \beta_2 β 2 ​ receptors. It is the drug of choice for anaphylaxis, severe post-cardiac arrest shock, symptomatic bradycardia refractory to atropine/pacing, and refractory septic shock.

Dosing: Hemodynamic infusions are typically titrated from 0.01 to 0.2 mcg/kg/min (or 2 to 10 mcg/min). Anaphylaxis doses are 0.3 mg IM (1:1,000) for standard emergencies, or 5 to 20 mcg IV boluses for peri-arrest states.

Biphasic Hemodynamic Actions: Epinephrine demonstrates distinct dose-dependent receptor affinities:

Low Doses (0.01–0.05 mcg/kg/min): β 1 \beta_1 β 1 ​ and β 2 \beta_2 β 2 ​ adrenergic effects dominate. Cardiac output rises due to increased heart rate and contractility, while SVR may decrease or remain neutral because of β 2 \beta_2 β 2 ​ -mediated vasodilation.

High Doses (> 0.05 mcg/kg/min): α 1 \alpha_1 α 1 ​ receptor stimulation overcomes β 2 \beta_2 β 2 ​ vasodilation. This leads to marked systemic vasoconstriction, rapid increases in SVR, MAP, and myocardial workload, along with persistent β 1 \beta_1 β 1 ​ -mediated tachycardia.

Adverse Metabolic Effects: Epinephrine stimulates skeletal muscle β 2 \beta_2 β 2 ​ receptors, which accelerates aerobic glycolysis and increases lactate production (hyperlactatemia). This occurs independently of tissue hypoxia and can lead to a misleading lactic acidosis, which clinicians must distinguish from worsening perfusion.

Dopamine

Dopamine is a precursor to norepinephrine and epinephrine. While its clinical use has significantly declined due to the risk of tachyarrhythmias and increased mortality in cardiogenic shock (demonstrated in the SOAP II trial), it remains highly tested on transport exams.

Dose-Dependent Receptor Activation:

Low Dose (1–5 mcg/kg/min - "Renal Dose"): Stimulates D 1 D_1 D 1 ​ and D 2 D_2 D 2 ​ receptors, inducing vasodilation in the renal, mesenteric, and coronary beds. Note: Clinical trials have disproven that this prevents renal failure, but the physiological concept is tested.

Intermediate Dose (5–10 mcg/kg/min - "Inotropic Dose"): Stimulates β 1 \beta_1 β 1 ​ receptors. This promotes myocardial contractility, increases heart rate, and stimulates the release of endogenous norepinephrine, enhancing cardiac output.

High Dose (10–20 mcg/kg/min - "Vasopressor Dose"): Stimulates α 1 \alpha_1 α 1 ​ receptors, resulting in systemic vasoconstriction and elevated SVR. Doses exceeding 20 mcg/kg/min produce intense vasoconstriction resembling pure alpha agonists, but with severe arrhythmogenic side effects.

Extravasation and Tissue Necrosis Management

Vasoactive medications administered through a peripheral IV carry a high risk of extravasation. The intense local α 1 \alpha_1 α 1 ​ stimulation causes severe vasoconstriction, leading to localized ischemia, hypoxia, and tissue necrosis.

Prevention: Central venous catheters (CVC) are preferred. If peripheral access must be used, utilize a large-bore IV (18G or larger) in a large proximal vein (e.g., antecubital fossa), confirm patency frequently, and limit infusion duration to under 12–24 hours.

Active Extravasation Protocol:

Stop the infusion immediately. Do not flush the line.

Do not remove the IV catheter. Attach a syringe and aspirate as much residual drug from the catheter hub as possible.

Administer the antidote: Phentolamine (Regitine). Phentolamine is a competitive, non-selective alpha-adrenergic receptor antagonist that reverses local vasoconstriction.

Dosing & Preparation: Dilute 5 to 10 mg of phentolamine in 10 to 15 mL of 0.9% normal saline.

Administration: Inject the solution subcutaneously/intradermally directly through the IV catheter (if still patent) and then infiltrate the remaining solution in a circular pattern around the blanched, ischemic area using a fine-gauge needle (25G or 27G). This must be done within 12 hours of the event to prevent tissue sloughing.

Alternatives: If phentolamine is unavailable, topical 2% nitroglycerin paste or terbutaline infiltration can be used to promote vasodilation.

Physiological Considerations: pH and Catecholamine Responsiveness

Severe acidemia (pH < 7.2) significantly blunts the hemodynamic effectiveness of catecholamines. An abundance of hydrogen ions alters the tertiary structure of adrenergic receptors and uncouples G-proteins from their intracellular signaling pathways. In cases of refractory shock with profound metabolic or respiratory acidosis, the underlying acid-base balance must be corrected (via ventilation optimization or targeted buffer therapy, when indicated) to restore the efficacy of circulating vasopressors.

Loading diagram... Vasoactive Extravasation Management Algorithm